ASX Release
20 November 2018
R&D Tax Incentive
Resonance Health Limited (ASX: RHT) ("Resonance Health" or "Company") is pleased to announce that the Company has received an R&D Tax Incentive refund of A$326,470 for the 2017/2018 financial year.
The R&D Tax Incentive is an Australian Government program under which companies receive cash refunds for 43.5% of their eligible expenditure on research and development over the 12-month period.
The incentive refund results from Resonance Health's ongoing studies on liver and metabolic disease, improvements to core services, and the finalised development of FerriSmart®, the Company's automated tool that uses artificial intelligence to quantify liver iron concentration.
The Company's unaudited cash balance as of 20 November 2018 is approximately A$2.04 million.
We look forward to providing further R&D updates as work progresses.
Alison Laws
Chief Executive Officer
For further information please contact: Chad Tondut
Communications Manager, Resonance Health
E:chadt@resonancehealth.com P: +61 (0)8 9286 5300
Resonance Health Ltd. ABN: 96 006 762 492
141 Burswood Road, Burswood, WA 6100, AUSTRALIA Postal: PO Box 71, Burswood, WA, 6100, AUSTRALIAwww.resonancehealth.com T + 61 8 9286 5300
info@resonancehealth.com